Clinical applications of fibroblast activation protein-targeted theranostics in oncologic and nononcologic disease: Current status and future directions
{"title":"Clinical applications of fibroblast activation protein-targeted theranostics in oncologic and nononcologic disease: Current status and future directions","authors":"Hao Fu, Wei Guo, Jingxiong Huang, Hua Wu, Haojun Chen","doi":"10.1002/ird3.46","DOIUrl":null,"url":null,"abstract":"<p>Quinoline-based fibroblast activation protein (FAP) inhibitor (FAPI)-based positron emission tomography (PET) imaging and radioligand therapy (RLT) are being investigated for use in a wide variety of diseases, and recent results have been promising. This review summarizes the current status of FAPI radiopharmaceuticals in PET imaging of malignant tumors and benign conditions and compares their diagnostic efficacy with <sup>18</sup>F-fluorodeoxyglucose. In addition, we summarize the previously published FAP-targeted RLT data and discuss its current clinical use and future potential. Our qualitative summary can inform future research directions, medical guidelines, and optimal clinical decision-making.</p>","PeriodicalId":73508,"journal":{"name":"iRadiology","volume":"1 4","pages":"340-361"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ird3.46","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iRadiology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ird3.46","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Quinoline-based fibroblast activation protein (FAP) inhibitor (FAPI)-based positron emission tomography (PET) imaging and radioligand therapy (RLT) are being investigated for use in a wide variety of diseases, and recent results have been promising. This review summarizes the current status of FAPI radiopharmaceuticals in PET imaging of malignant tumors and benign conditions and compares their diagnostic efficacy with 18F-fluorodeoxyglucose. In addition, we summarize the previously published FAP-targeted RLT data and discuss its current clinical use and future potential. Our qualitative summary can inform future research directions, medical guidelines, and optimal clinical decision-making.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
